NasdaqGM:KROS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Keros Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KROS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: KROS's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

0.9%

KROS

3.5%

US Biotechs

-0.9%

US Market


1 Year Return

n/a

KROS

36.8%

US Biotechs

19.6%

US Market

Return vs Industry: Insufficient data to determine how KROS performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how KROS performed against the US Market.


Shareholder returns

KROSIndustryMarket
7 Day0.9%3.5%-0.9%
30 Day-8.9%6.0%3.0%
90 Day38.5%19.2%11.5%
1 Yearn/a39.1%36.8%22.3%19.6%
3 Yearn/a30.5%23.6%45.3%35.7%
5 Yearn/a43.7%32.8%124.8%99.9%

Long-Term Price Volatility Vs. Market

How volatile is Keros Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Keros Therapeutics undervalued compared to its fair value and its price relative to the market?

11.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KROS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KROS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KROS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: KROS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KROS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KROS is overvalued based on its PB Ratio (11.1x) compared to the US Biotechs industry average (4.3x).


Next Steps

Future Growth

How is Keros Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-31.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KROS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KROS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KROS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KROS is forecast to have no revenue next year.

High Growth Revenue: KROS is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KROS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Keros Therapeutics performed over the past 5 years?

-247.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: KROS is currently unprofitable.

Growing Profit Margin: KROS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if KROS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare KROS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KROS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: KROS has a negative Return on Equity (-28.63%), as it is currently unprofitable.


Next Steps

Financial Health

How is Keros Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: KROS's short term assets ($136.4M) exceed its short term liabilities ($6.8M).

Long Term Liabilities: KROS's short term assets ($136.4M) exceed its long term liabilities ($663.0K).


Debt to Equity History and Analysis

Debt Level: KROS is debt free.

Reducing Debt: KROS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KROS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: KROS has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 109.1% each year.


Next Steps

Dividend

What is Keros Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KROS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KROS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KROS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KROS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KROS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Jas Seehra (65 yo)

no data

Tenure

US$694,519

Compensation

Dr. Jasbir Seehra, also known as Jas, Ph.D., has been Chief Executive Officer of Keros Therapeutics Inc., since 2016 and serves as its President, Treasurer and Secretary and has been its Director since Dec...


CEO Compensation Analysis

Compensation vs Market: Jas's total compensation ($USD694.52K) is below average for companies of similar size in the US market ($USD3.85M).

Compensation vs Earnings: Insufficient data to compare Jas's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Jasbir Seehra
Presidentno dataUS$694.52k1.05%
$ 17.5m
Jennifer Lachey
Chief Scientific Officer1.58yrsUS$414.29k0.12%
$ 2.0m
Claudia Ordonez
Chief Medical Officer1.33yrsUS$201.91k0.11%
$ 1.8m
Keith Regnante
Chief Financial Officer0.92yrno datano data

1.3yrs

Average Tenure

52yo

Average Age

Experienced Management: KROS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Jasbir Seehra
Presidentno dataUS$694.52k1.05%
$ 17.5m
Carl Gordon
Independent Director0.83yrno datano data
Tomer Kariv
Independent Director1yrno datano data
Julius Knowles
Independent Director4.75yrsno datano data
Mary Gray
Director0.083yrno datano data
Ran Nussbaum
Independent Chairman of the Board4.75yrsno datano data
Nima Farzan
Independent Director0.83yrno data0.018%
$ 304.3k
Mary Bouxsein
Member of Scientific Advisory Boardno datano datano data
Vicki Rosen
Member of Scientific Advisory Boardno datano datano data
Paul Yu
Member of Scientific Advisory Boardno datano datano data

1.0yrs

Average Tenure

57yo

Average Age

Experienced Board: KROS's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: KROS only recently listed within the past 12 months.


Top Shareholders

Company Information

Keros Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Keros Therapeutics, Inc.
  • Ticker: KROS
  • Exchange: NasdaqGM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.659b
  • Shares outstanding: 23.18m
  • Website: https://www.kerostx.com

Number of Employees


Location

  • Keros Therapeutics, Inc.
  • 99 Hayden Avenue
  • Suite 120
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KROSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 2020

Biography

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculos...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 00:19
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.